Sep 22, 2026
ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%
ImmunityBio (IBRX) shares surged by nearly 10% after its founder, Dr. Patrick Soon-Shiong, met with Turkish President Recep Tayyip Erdogan, indicating progress on the company's expansion into Turkey. This development follows the FDA approval of ImmunityBio's immunotherapy drug Anktiva, which has already been accepted in 34 countries and significantly boosted the company's Q2 revenues. Institutional investors are also bullish on IBRX, increasing their combined holdings by over 62% in the last quarter.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish
Sep 21, 2026
Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode
ImmunityBio (IBRX) shares saw a significant jump after founder Patrick Soon-Shiong teased Nant's upcoming launch of blockchain and tokenized stocks, following the SEC's new "Innovation Exemption." This has led to retail speculation that IBRX shares could be tokenized, with traders discussing the potential impact on short sellers and the efficiency of capital markets. Nant Global Finance is actively building a blockchain-enabled capital-markets platform, integrating various capabilities through acquisitions.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Somewhat-Bullish
Sep 14, 2026
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
PDS Biotech announced the initial closing of a PIPE financing, raising $11.3 million, led by Nant Capital. The financing aims to fund clinical programs and advance PDS0301 into late-stage development. Additionally, Dr. Patrick Soon-Shiong and James Banaag have been appointed to the company's board of directors.
Company relevance
82.76%
Company sentiment
Bullish
Overall sentiment
Bullish